Market Cap | 302.25M | P/E | - | EPS this Y | 11.30% | Ern Qtrly Grth | - |
Income | -120.74M | Forward P/E | -2.25 | EPS next Y | -4.70% | 50D Avg Chg | -26.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 16.00% |
Dividend | N/A | Price/Book | 1.40 | EPS next 5Y | - | 52W High Chg | -44.00% |
Recommedations | 1.80 | Quick Ratio | 5.94 | Shares Outstanding | 78.89M | 52W Low Chg | 176.00% |
Insider Own | 1.18% | ROA | -41.33% | Shares Float | 54.21M | Beta | 2.40 |
Inst Own | 73.10% | ROE | -74.54% | Shares Shorted/Prior | 5.22M/4.63M | Price | 4.52 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 577,762 | Target Price | 19.43 |
Oper. Margin | - | Earnings Date | - | Volume | 481,870 | Change | -2.80% |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
HC Wainwright & Co. | Buy | Jul 8, 24 |
William Blair | Outperform | Jun 10, 24 |
Canaccord Genuity | Buy | May 16, 24 |
HC Wainwright & Co. | Buy | May 15, 24 |
Chardan Capital | Buy | Mar 21, 24 |
Canaccord Genuity | Buy | Mar 20, 24 |
HC Wainwright & Co. | Buy | Mar 19, 24 |
Leerink Partners | Outperform | Nov 30, 23 |
HC Wainwright & Co. | Buy | Oct 9, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Hoey Timothy | Chief Scientific Off.. Chief Scientific Officer | Aug 29 | Sell | 4.26 | 7,243 | 30,855 | 247,396 | 08/29/23 |
Hoey Timothy | Chief Scientific Off.. Chief Scientific Officer | Aug 16 | Sell | 3.81 | 4,007 | 15,267 | 254,639 | 08/18/23 |
Tingley Whittemore | Chief Medical Office.. Chief Medical Officer | Aug 16 | Sell | 3.81 | 5,563 | 21,195 | 76,437 | 08/18/23 |
PATTERSON LEONE D | Chief Fin. and Bus... Chief Fin. and Bus. Officer | Aug 16 | Sell | 3.81 | 4,452 | 16,962 | 64,542 | 08/18/23 |
Ali Faraz | Chief Executive Offi.. Chief Executive Officer | Aug 16 | Sell | 3.81 | 5,563 | 21,195 | 119,437 | 08/18/23 |
GOEDDEL DAVID V | Director Director | Jan 17 | Buy | 2.51 | 185,151 | 464,729 | 9,800,535 | 01/19/23 |
Srivastava Deepak | Director Director | Nov 21 | Buy | 2.60 | 230,769 | 599,999 | 372,435 | 12/09/22 |
Srivastava Deepak | Director Director | Nov 21 | Buy | 2.60 | 230,769 | 599,999 | 372,435 | 12/09/22 |
Casdin Eli | Director Director | Nov 17 | Buy | 2.60 | 2,492,042 | 6,479,309 | 6,078,860 | 11/25/22 |
Hoey Timothy | Chief Scientific Off.. Chief Scientific Officer | Apr 26 | Sell | 10.13 | 1,353 | 13,706 | 198,646 | 04/28/22 |